Search Results for "Nct00632723"
18:08 EDT 19th May 2013 | BioPortfolio
Original Source: IRESSA™ (Gefitinib) in Breast Cancer Patients
This is a phase II trial to assess whether IRESSA™ (gefitinib) has anti-tumour efficacy in patients with breast cancer. The trial proposes to enter 27 patients who have acquired resistance to tamoxifen and 27 patients with ER negative tumours. However for each of these two types of patients recruitment will stop after 14 patients have been entered in order to confirm that IRESSA™ (gefitinib)has anti-tumour efficacy. If no patient out of 14 in a group has shown clinical b...
Matching Channels
None
Matching News
None
Matching PubMed Articles
None
Search Whole site using Google
Loading
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
